Floatz logo

Anti-Bcma Car-T Cells

Lymphoblastic Leukemia

Anhui Provincial HospitalCell therapyN/AActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the Lymphoblastic Leukemia cohort.

Asset / SponsorPhaseRating
IMMUNOGLOBULIN G1 (HUMAN-RAT MONOCLONAL CAMPATH-1H .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD52), DISULFIDE WITH HUMAN-RAT MONOCLONAL CAMPATH-1H LIGHT CHAIN, DIMER
Gruppo Italiano Trapianto di Midollo Osseo
Phase 2/3B
Donor Lymphocyte Preparation Depleted Of Host Functional Alloreactive T-Cells
Kiadis Pharma
Phase 2/3CCC
Anti-Cd19 Car T-Cells
KK Women's and Children's Hospital
Phase 2CCC
gh21
KK Women's and Children's Hospital
Phase 1/2CCC
gh55
KK Women's and Children's Hospital
Phase 1/2CCC
Beam-201
Beam Therapeutics Inc.
Phase 1/2CCC

Same molecule, other indications

Anti-Bcma Car-T Cells is also rated in:

plasma cell myelomaDormant
B
Indicative ·
63 / 100
View asset →
plasma cell myelomaDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →